The safety profile of drotrecogin alfa (activated)

This publication has 29 references indexed in Scilit:

• Second Course of Recombinant Human Activated Protein C Delivered to a Severely Septic Patient After Recent Surgery
  Journal of Trauma: Injury, Infection & Critical Care, 2008
• The Neuropathology of Septic Shock
  Brain Pathology, 2004
• Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
  JAMA, 2003
• Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor
  Biochemical Journal, 2003
• Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
  Critical Care, 2003
• Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
  Critical Care, 2003
• Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
  Critical Care Medicine, 2001
• High-Dose Antithrombin III in Severe Sepsis
  JAMA, 2001
• The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant Pathway
  Journal of Autoimmunity, 2000
• HUMAN PROTEIN C: INACTIVATION OF FACTORS V AND VIII IN PLASMA BY THE ACTIVATED MOLECULE*
  Annals of the New York Academy of Sciences, 1981